How many employees does Puma Biotechnology, Inc. have?

Puma Biotechnology, Inc. reported 179 employees for the fiscal year ending Dec 2025, in the annual report it filed on February 26, 2026. That is up 4.1% from a year earlier.

What is Puma Biotechnology, Inc.'s revenue per employee?

Puma Biotechnology, Inc. brought in $228M of revenue in fiscal Dec 2025, which is $1.28M per employee. That ranks 26 of 108 companies we track in Biotechnology, where the median is $459K.

Where do these numbers come from?

Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Company data

Puma Biotechnology, Inc. employees and revenue per employee

PBYI · Biotechnology · $524M market cap

Puma Biotechnology, Inc. had 179 employees at the end of fiscal Dec 2025, up 4.1% from a year earlier. Revenue for the year was $228M, down 0.9% from a year earlier, or $1.28M per employee. Revenue fell while headcount grew.

Employees

179

+4.1% YoY

Revenue

$228M

-0.9% YoY

Revenue / employee

$1.28M

Peer median $459K

Rank in industry

26 of 108

Biotechnology

Headcount against revenue

Both lines start at 100 in the first year we hold, so you can see which one grew faster.

EmployeesRevenueIndexed to 100 in Dec 2017

Hover a year for the numbers.

PBYI employees and revenue by fiscal year
Year ending	Employees	Revenue	Per employee	Staff YoY	Revenue YoY
Dec 2025	179	$228M	$1.28M	+4.1%	-0.9%
Dec 2024	172	$230M	$1.34M	-7.0%	-2.2%
Dec 2023	185	$236M	$1.27M	-3.6%	+3.3%
Dec 2022	192	$228M	$1.19M	-2.0%	-9.9%
Dec 2021	196	$253M	$1.29M	-26.6%	+12.5%
Dec 2020	267	$225M	$843K	-0.7%	-17.3%
Dec 2019	269	$272M	$1.01M	-1.1%	+8.5%
Dec 2018	272	$251M	$923K	-14.5%	+806.1%
Dec 2017	318	$27.7M	$87K	—	—

Open roles: we have not matched a verified job board for this company yet.

Employees, last six fiscal years

Revenue per employee, last six fiscal years

Puma Biotechnology, Inc. against similar companies

The closest industry peers by revenue, from Biotechnology.

Company	Employees	Revenue	Revenue / employee	Shape
LGND Ligand Pharmaceuticals Incorporated	47	$268M	$5.70M	Leaner
ANAB AnaptysBio, Inc.	104	$235M	$2.26M	Leaner
IDYA IDEAYA Biosciences, Inc.	145	$219M	$1.51M	Efficient growth
PBYI Puma Biotechnology, Inc.	179	$228M	$1.28M	Hiring into decline
ARVN Arvinas, Inc.	246	$263M	$1.07M	Contracting
VCEL Vericel Corporation	398	$276M	$694K	Efficient growth
RYTM Rhythm Pharmaceuticals, Inc.	414	$190M	$458K	Hiring ahead
RCUS Arcus Biosciences, Inc.	601	$247M	$411K	Contracting
IOVA Iovance Biotherapeutics, Inc.	975	$264M	$270K	Efficient growth

Every Healthcare company

Questions about Puma Biotechnology, Inc.

How many employees does Puma Biotechnology, Inc. have?: Puma Biotechnology, Inc. reported 179 employees for the fiscal year ending Dec 2025, in the annual report it filed on February 26, 2026. That is up 4.1% from a year earlier.
What is Puma Biotechnology, Inc.'s revenue per employee?: Puma Biotechnology, Inc. brought in $228M of revenue in fiscal Dec 2025, which is $1.28M per employee. That ranks 26 of 108 companies we track in Biotechnology, where the median is $459K.
Where do these numbers come from?: Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Free game

Think you can pick better than the S&P 500?

Pick 15 stocks, lock them in, and we score them against the index every trading day for ten years. Free, with a public leaderboard.

Enter the challenge

More data

Compare PBYI with the rest of the market

See who earns the most per employee, who is hiring, and who is cutting, across every company we track.

Leaderboard Healthcare

Source: employee counts and revenue as stated in Puma Biotechnology, Inc.'s annual reports (Form 10-K), latest filed February 26, 2026. This is data, not a recommendation to buy or sell PBYI.